Biomaterial Database

Influencing parenteral histamine2-receptor antagonist use. 1989

G P Sesin, and P S Provost, and E M O'Keefe

UI	MeSH Term	Description	Entries
D007262	Infusions, Intravenous	The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.	Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D010607	Pharmacy Service, Hospital	Hospital department responsible for the receiving, storing, and distribution of pharmaceutical supplies.	Clinical Pharmacy Service,Hospital Pharmacy Service,Pharmacy Service, Clinical,Hospital Pharmaceutic Service,Hospital Pharmaceutical Service,Hospital Pharmacy Services,Pharmaceutic Service, Hospital,Pharmaceutical Service, Hospital,Service, Clinical Pharmacy,Service, Hospital Pharmaceutic,Service, Hospital Pharmaceutical,Service, Hospital Pharmacy,Clinical Pharmacy Services,Hospital Pharmaceutic Services,Hospital Pharmaceutical Services,Pharmaceutic Services, Hospital,Pharmaceutical Services, Hospital,Pharmacy Services, Clinical,Pharmacy Services, Hospital,Services, Clinical Pharmacy,Services, Hospital Pharmaceutic,Services, Hospital Pharmaceutical,Services, Hospital Pharmacy
D004363	Drug Utilization	The utilization of drugs as reported in individual hospital studies, FDA studies, marketing, or consumption, etc. This includes drug stockpiling, and patient drug profiles.	Utilization, Drug,Drug Utilizations,Utilizations, Drug
D006635	Histamine H2 Antagonists	Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood.	Antihistaminics, H2,H2 Receptor Blockader,Histamine H2 Antagonist,Histamine H2 Blocker,Histamine H2 Receptor Antagonist,Histamine H2 Receptor Antagonists,Histamine H2 Receptor Blockader,Histamine H2 Receptor Blockaders,Antagonists, Histamine H2,Blockaders, Histamine H2 Receptor,H2 Receptor Blockaders,Histamine H2 Blockers,Receptor Antagonists, Histamine H2,Receptor Blockaders, H2,Antagonist, Histamine H2,Blockader, H2 Receptor,Blockaders, H2 Receptor,Blocker, Histamine H2,Blockers, Histamine H2,H2 Antagonist, Histamine,H2 Antagonists, Histamine,H2 Antihistaminics,H2 Blocker, Histamine,H2 Blockers, Histamine,Receptor Blockader, H2
D006785	Hospitals, University	Hospitals maintained by a university for the teaching of medical students, postgraduate training programs, and clinical research.	University Hospitals
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

G P Sesin, and P S Provost, and E M O'Keefe

Economic impact of inappropriate histamine2-receptor antagonist use.

January 1997, Clinical therapeutics,

G P Sesin, and P S Provost, and E M O'Keefe

Comparison of the Parenteral histamine2-receptor antagonists.

October 1989, DICP : the annals of pharmacotherapy,

G P Sesin, and P S Provost, and E M O'Keefe

Histamine2 receptor antagonist use and decline in cognitive function among community dwelling elderly.

November 2004, Pharmacoepidemiology and drug safety,

G P Sesin, and P S Provost, and E M O'Keefe

Cimetidine and other histamine2-receptor antagonist use in relation to risk of breast cancer.

April 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,

G P Sesin, and P S Provost, and E M O'Keefe

Combination sucralfate and histamine2-antagonist therapy.

May 1994, The Annals of pharmacotherapy,

G P Sesin, and P S Provost, and E M O'Keefe

Relationship between histamine2-receptor antagonist medications and risk of invasive breast cancer.

January 2008, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,

G P Sesin, and P S Provost, and E M O'Keefe

Costs associated with the inappropriate route of administration of parenteral histamine2-receptor antagonists.

November 1987, Drug intelligence & clinical pharmacy,

G P Sesin, and P S Provost, and E M O'Keefe

Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use.

August 1999, The Journal of pharmacology and experimental therapeutics,

G P Sesin, and P S Provost, and E M O'Keefe

Comment: parenteral H2-receptor antagonist intervention.

June 1991, DICP : the annals of pharmacotherapy,

G P Sesin, and P S Provost, and E M O'Keefe

Concomitant Administration of a Histamine2 Receptor Antagonist and Proton Pump Inhibitor Enhances Gastric Acid Suppression.

December 2015, Pharmacotherapy,